A confluence of topics dealing with mental health, substance abuse, health, public health, Social Work, education, politics, the humanities, and spirituality at the micro, mezzo, and macro levels. In short, this blog is devoted to the improvement of the quality of life of human beings in the universe.
Saturday, December 2, 2017
Subscribe to Markham's Behavioral Health
Follow Markham's Behavioral Health by subscribing by email in upper right hand corner. Keep up with MH information relevant to the practice of a working mental health professional.
Smart phone addiction alters brain chemistry
From Health Day on 11/30/17:
THURSDAY, Nov. 30, 2017 (HealthDay News) -- Teens fixated on their smartphones experience changes to their brain chemistry that mirror those prompted by addiction, a new study suggests.
For more click here.
THURSDAY, Nov. 30, 2017 (HealthDay News) -- Teens fixated on their smartphones experience changes to their brain chemistry that mirror those prompted by addiction, a new study suggests.
For more click here.
Friday, December 1, 2017
Monthly injections of buprenorphine approved for opioid addiction treatment
From the American Psychiatric Association Psychiatric News Alert on 12/01/17
The Food and Drug Administration (FDA) has approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adults who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. Sublocade is indicated for patients who have been on a stable dose of buprenorphine treatment for a minimum of seven days and is meant to be used as part of a complete treatment program that includes counseling and psychosocial support.
For more click here.
The Food and Drug Administration (FDA) has approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adults who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. Sublocade is indicated for patients who have been on a stable dose of buprenorphine treatment for a minimum of seven days and is meant to be used as part of a complete treatment program that includes counseling and psychosocial support.
For more click here.
Monday, November 20, 2017
Having a dog can extend a single person's life
From Health Day 11/17/17
FRIDAY, Nov. 17, 2017 (HealthDay News) -- Here's to keeping your health on a tight leash: New research suggests that having a dog might boost a single person's life span.
The study tracked more than 3.4 million Swedes, middle-aged and older, for 12 years. All were free of heart disease at the beginning of the study.
The researchers reported that dog owners who lived alone were 11 percent less likely to die of heart disease and a third less likely to die from any cause, compared with those who lived alone and didn't have a dog.
For more click here.
Friday, November 17, 2017
Friday, November 3, 2017
Subscribe to:
Posts (Atom)